In vivo studies play a central role in preclinical development by generating critical efficacy, tolerability, and biologically relevant data that guide development decisions. Well-designed studies enable sponsors to evaluate therapeutic potential and select appropriate development paths prior to entering clinical programs.
In this BRIDGE Sweden webinar, Matilda Bäckberg and Olivia Merinder from Legado Bio will present how different types of in vivo studies support drug development across therapeutic modalities, including disease models, proof of concept studies, dose response evaluations, and toxicity and tolerability assessments.
The session will highlight how industrially relevant study design, scientific rigor, and 3R principles contribute to high-quality, reproducible data supporting informed decision making in preclinical drug development.
This webinar is aimed at researchers, startups, and organizations working with drug development and preclinical research.
Sign up: Follow this LINK
